NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
NextCure, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.67−0.57 (-9.13%)
Close on Oct 19, 2026
- Market cap
- $30.11M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$6.26 (−52.47%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $30.11M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.48
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$42.75M
- EPS, diluted
- -$10.26
- Book value per share
- $2.29
- Diluted shares
- 5M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$43.90M
Net income
-$42.75M
EPS, diluted
-$10.26
Free cash flow
–
Reported periodTrailing twelve months